Drug Profile
FBH 001
Alternative Names: CCHF (FBH-001); FBH-001Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Fabentech
- Developer Fabentech; INSERM; United States Army Medical Research Institute of Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crimean-Congo haemorrhagic fever virus infections
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Crimean-Congo haemorrhagic fever virus infections (Prevention) in France (Parenteral) (Fabentech pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Crimean-Congo-haemorrhagic-fever-virus-infections(Prevention) in France (Parenteral)
- 22 Jul 2016 Preclinical trials in Crimean-Congo haemorrhagic fever virus infections (Prevention) in France (Parenteral)